Financial reports
10-Q
2018 Q3
Quarterly report
8 Nov 18
10-Q
2018 Q2
Quarterly report
9 Aug 18
10-Q
2018 Q1
Quarterly report
8 May 18
10-K
2017 FY
Annual report
1 Mar 18
10-Q
2017 Q3
Quarterly report
2 Nov 17
10-Q
2017 Q2
Quarterly report
8 Aug 17
10-Q
2017 Q1
Quarterly report
9 May 17
10-K
2016 FY
Annual report
7 Mar 17
10-Q
2016 Q3
Quarterly report
2 Nov 16
10-Q
2016 Q2
Quarterly report
3 Aug 16
Current reports
8-K
Completion of Acquisition or Disposition of Assets
15 Feb 19
8-K
Entry into a Material Definitive Agreement
7 Jan 19
8-K
Departure of Directors or Certain Officers
2 Jan 19
8-K
Regulation FD Disclosure
6 Dec 18
8-K
FDA Approves VitrakviĀ®Ā (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion1,2
27 Nov 18
8-K
Loxo Oncology Reports Third Quarter 2018 Financial Results
8 Nov 18
8-K
Other Events
17 Sep 18
8-K
Loxo Oncology Reports Second Quarter 2018 Financial Results
9 Aug 18
8-K
Departure of Directors or Certain Officers
14 Jun 18
8-K
Regulation FD Disclosure
4 Jun 18
Registration and prospectus
15-12B
Securities registration termination
25 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Feb 19
POSASR
Automatic shelf registration (post-effective amendment)
15 Feb 19
POS AM
Prospectus update (post-effective amendment)
15 Feb 19
SC 14D9/A
Tender offer solicitation (amended)
15 Feb 19
Proxies
DEFA14A
Additional proxy soliciting materials
30 Apr 18
DEF 14A
Definitive proxy
30 Apr 18
DEF 14A
Definitive proxy
1 May 17
DEFA14A
Additional proxy soliciting materials
1 May 17
DEF 14A
Definitive proxy
18 Apr 16
DEFA14A
Additional proxy soliciting materials
18 Apr 16
DEF 14A
Definitive proxy
23 Apr 15
DEFA14A
Additional proxy soliciting materials
23 Apr 15
Other
EFFECT
Notice of effectiveness
22 Feb 19
UPLOAD
Letter from SEC
23 Oct 18
CORRESP
Correspondence with SEC
6 Sep 18
UPLOAD
Letter from SEC
22 Aug 18
CT ORDER
Confidential treatment order
16 Apr 18
CT ORDER
Confidential treatment order
20 Nov 17
EFFECT
Notice of effectiveness
16 Nov 16
CORRESP
Correspondence with SEC
14 Nov 16
UPLOAD
Letter from SEC
14 Nov 16
CT ORDER
Confidential treatment order
27 Apr 16
Ownership
SC 13G/A
Beneficial ownership report (amended)
14 Feb 20
SC 13G/A
Loxo Oncology, Inc.
8 Jan 20
SC 13D/A
Loxo Oncology, Inc.
15 Feb 19
SC 13D/A
Beneficial ownership report (amended)
15 Feb 19
4
Naarden Jacob Van
15 Feb 19
4
Nisha Nanda
15 Feb 19
4
Avi Z. Naider
15 Feb 19
4
TIMOTHY M MAYLEBEN
15 Feb 19
4
Lori Anne Kunkel
15 Feb 19
4
Steve Harr
15 Feb 19